Dr. Alexander Nyström

CV

2013-present       Group Leader, Medical Center – University of Freiburg, Freiburg, Germany

2010-2013           Postdoctoral Fellow, University of Freiburg, Freiburg, Germany (Laboratory of Dr. L. Bruckner-                                        Tuderman)

2007-2009           Postdoctoral Fellow, Thomas Jefferson University, Philadelphia, USA (Laboratory of Dr. R. Iozzo)

2003-2006           Ph.D., Lund University, Lund, Sweden

1997-2002           M.S. in Molecular Biology, Lund University, Lund, Sweden

Selected Publications

• Bornert O, Hogervorst M, Nauroy P, Bischof J, Swildens J, Athanasiou I, Tufa SF, Keene DR, Kiritsi D, Hainzl S, Murauer EM, Marinkovich MP, Platenburg G, Hausser I, Wally V, Ritsema T, Koller U, Haisma EM, Nyström A. 2021. QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study. J Invest Dermatol, 141(4):883-893.

• Nyström A¹, Bornert O, Kühl T, Gretzmeier C, Thriene K, Dengjel J, Pfister-Wartha A, Kiritsi D, Bruckner-Tuderman L. 2018. Impaired lymphoid extracellular matrix impedes antibacterial immunity in epidermolysis bullosa. Proc Natl Acad Sci U S A. 115:E705-E714. (¹Corresponding author)

• Bornert O, Kühl T, Bremer J, van den Akker PC, Pasmooij AMG, Nyström A. 2016. Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy. Mol Ther. 24,1302-11.

• Nyström A, Thriene K, Mittapalli V, Kern JS, Kiritsi D, Dengjel J, Bruckner-Tuderman L. 2015. Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms. EMBO Mol Med. 7:1211-28.

• Nyström A, Velati D, Mittapalli V, Fritsch A , Kern JS, Bruckner-Tuderman L. 2013. Collagen VII plays a dual role in skin wound healing. J Clin Invest. 123:3498-509.

FRIAS Research Project

MatrixCode: matrisome pathology

The “extracellular matrix” (ECM) encompasses all secreted, deposited, and soluble proteins in the interstitial milieu. In recent years, our perspective on ECM has changed on the functional and protein level, as we now understand the ECM less as a passive “scaffold”, and more as integral part of the diverse, complex, and dynamic signaling environment sustaining healthy tissue. By improved understanding of these complex aspects of the so-called “matrisome”, our opportunities to develop targeted therapies interacting with these processes in disease, scarring, and regeneration will be strengthened. The MatrixCode project aims to decipher how pathophysiological signaling depends on biochemical and biophysical modifications of the ECM. MatrixCode is compiled of four sub-projects focusing on different aspects of ECM signaling within wound healing and tumor biology. MatrixCode will strengthen ECM research in Freiburg by creating a critical mass of scientists, and strengthening ties to collaboration partners in Strasburg and worldwide. MatrixCode will lay the foundation for subsequent collaborative funding initiatives.